Can Fite Bio (CANF) AI Stock Analysis

• Market Cap: 58.40M
• Dividend Yield: N/A
• Average Volume (3M): 11.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 8
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 3,893,155,000
• 10 Day Avg. Volume: 17,693,420
• 30 Day Avg. Volume: 11,264,846
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Can Fite Bio faces significant financial challenges, with declining revenues, high operational losses, and negative cash flow. The technical indicators suggest a bearish outlook, while valuation metrics highlight potential overvaluation risks. These factors cumulatively contribute to a low overall stock score, reflecting the need for substantial strategic adjustments to improve financial health and investor confidence.

Can Fite Bio Business Overview & Revenue Model

Company Description

Can Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of autoimmune-inflammatory, oncological, and liver diseases. Headquartered in Israel, the company leverages its proprietary technology platforms to develop pharmaceutical drugs that target specific pathways associated with these diseases, offering potential solutions for unmet medical needs. Key products in Can Fite's pipeline include Piclidenoson for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer and NAFLD/NASH, and CF602 for treating sexual dysfunction.

How the Company Makes Money

Can Fite BioPharma generates revenue primarily through licensing agreements, milestone payments, and royalties from partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve the out-licensing of Can Fite's drug candidates to partners who then undertake further development, manufacturing, and commercialization. The company earns milestone payments as the drug candidates progress through various stages of clinical trials and regulatory approvals. Additionally, once a partnered drug is commercialized, Can Fite receives royalties on product sales. The company may also engage in grant funding for specific research projects, which contributes to its revenue stream.

Can Fite Bio Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
743.00K	810.00K	853.00K	763.00K	2.03M
	Gross Profit
743.00K	810.00K	853.00K	763.00K	2.03M
	EBIT
-8.20M	-10.10M	-12.84M	-14.14M	-12.01M
	EBITDA
-8.18M	-10.08M	-12.83M	-14.13M	-11.99M
	Net Income Common Stockholders
-7.63M	-10.53M	-12.60M	-14.81M	-13.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.92M	7.98M	19.14M	8.34M	2.76M
	Total Assets
9.99M	9.28M	20.25M	9.52M	8.17M
	Total Debt
40.00K	62.00K	124.00K	67.00K	75.00K
	Net Debt
-4.24M	-2.92M	-4.27M	-8.20M	-2.62M
	Total Liabilities
3.75M	4.81M	5.87M	3.45M	5.73M
	Stockholders Equity
6.24M	4.47M	14.38M	6.07M	2.44M
Cash Flow		Free Cash Flow
-8.44M	-10.81M	-9.87M	-12.09M	-10.84M
	Operating Cash Flow
-8.44M	-10.80M	-9.86M	-12.06M	-10.83M
	Investing Cash Flow
498.00K	9.50M	-14.51M	-26.00K	-253.00K
	Financing Cash Flow
9.14M	0.00	20.46M	17.68M	10.17M

Can Fite Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 1.9 is above the 20-day moving average (MA) of 1.67, above the 50-day MA of 1.85, and below the 200-day MA of 2.47, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.

Can Fite Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
CANF	44 Neutral	58.40M	―		―	―	―
PLUR	40 Underperform	$37.58M	―	-1205.58%	―	89.92%	21.39%
ENLV	36 Underperform	$26.23M	―	-55.95%	―	―	53.95%

Can Fite Bio Corporate Events

Can-Fite’s Namodenoson Shows Promise in Treating Liver Cirrhosis

Can-Fite BioPharma Ltd. announced a significant clinical development with its drug Namodenoson, which successfully eliminated episodes of decompensated liver cirrhosis in a patient under a compassionate use program. The treatment led to significant symptom improvements and the potential for Namodenoson to provide a therapeutic option for patients awaiting liver transplants. This development addresses a critical need in the liver cirrhosis treatment market, projected to reach $15 billion in the U.S. by 2030, potentially positioning Can-Fite as a key player in this sector.

Can Fite Bio Nears Completion of Subsidiary Share Acquisition

Can Fite Bio has reached an agreement on significant terms for the acquisition of its subsidiary’s shares by a private investor, with the finalization expected soon. The acquisition marks a strategic development for the company, as it previously announced the purchase and has now completed the acquisition successfully, indicating potential positive impacts on its market positioning.